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Abstract
Aims: The purpose of this review was to investigate the effect of vitamin D supplements on hemoglobin
concentration in subjects aged 17.5–68 years old; using randomized controlled trials (RCTs).
Methods: Relevant RCT studies were identified from January 2000 to January 2019 by using MeSH terms in
PubMed, Embase, Cochrane Library, Clinical trials, Scopus databases and gray literature. The studies were reviewed
systematically, and quality assessments were evaluated by the guidelines of the Cochrane risk of bias. The effect of
vitamin D supplements (n = 14) on hemoglobin concentration was considered as primary outcome, while its effects
on the levels of ferritin, transferrin saturation and iron status were derived as secondary outcomes. In total, 1385
subjects with age range of 17.5 to 68 years old were examined for 3 h to 6 months; Mean (standard deviation) or
median interquartile changes in the hemoglobin concentration in each treatment group was recorded for meta-
analysis.
Results: Fourteen RCTs met the inclusion criteria. Current study findings propose that vitamin D supplementation
leads to a non-significant reduction in hemoglobin levels in subjects (17.5–68 years old) [std. mean difference
(SMD): 0.01; 95% CI: − 0.28, 0.29; P = 0.95], also it has no significant effect on ferritin concentrations [std. mean
difference (SMD): -0.01; 95% CI: [− 0.20, 0.18; P = 0.91]. However, vitamin D supplementation demonstrated positive
effects on transferrin saturation [mean difference (MD): 1.54; 95% CI: 0.31, 2.76; P = 0.01] and iron status [std. mean
difference (SMD): 0.24; 95% CI: − 0.09, 0.39; P = 0.002].
Conclusion: Current review concluded that supplementation with vitamin D had no significant effect on hemoglobin
and ferritin levels while positive effects on transferrin saturation and iron status were observed. Further clinical studies
are required to determine the actual effect of this intervention on hemoglobin levels.
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Introduction
Anemia is one of the most prevalent health problems
worldwide. It is believed that this disease is respon-
sible for a large portion of the financial burdens on
communities [1, 2]. Iron deficiency is the most com-
mon form of the disease and occurs in over 50% of
patients worldwide. According to the World Health
Organization (WHO), more than one billion people
are currently suffering from iron deficiency [1, 3, 4].
Several conditions, such as gastrointestinal disease,
chronic heart disease (CHD), chronic kidney disease
(CKD), and inflammatory diseases increase the risk of
anemia [5–13]. It is believed that these conditions
could decrease the quality of life as well as causing
great impairments in cognitive functions and increase
the prevalence of fatigue and other physical dysfunc-
tions [14–18]. As a result, attempts to improve the
prevention and treatment of anemia or the use of po-
tential therapies can help to reduce the burden of this
disease [19].
Vitamin D is a fat soluble vitamin that can be acquired
from regimen (ergocalciferol from plant sterols) and be
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synthesized from direct exposure to sunlight (cholecal-
ciferol) [20]. This vitamin is hydroxylated as 25-
hydroxyvitamin D (25OHD) in the liver and then con-
verted to its final form, Calcitriol (1, 25 (OH) 2D), in
the kidney cells [20, 21]. Vitamin D appears to be asso-
ciated with the prevention of chronic disease and
modulation of immunity, the regulation of cellular
growth, and the differentiation and induction of
erythropoiesis in bone marrow cells [22–25]. Several
observational studies have indicated that there is a re-
verse relationship between vitamin D levels and anemia
in adults [25–28]. Calcitriol (1,25-hydroxyvitamin D)
could stimulate erythrocyte precursor cell receptors,
which promotes the erythroid progenitor cells matur-
ation and proliferation [29]. It has also been reported
that anti-inflammatory effects of vitamin D could down
regulate mRNA expression of hepcidin levels [30]. The
antimicrobial hepcidin peptides are believed to be asso-
ciated with absorption and release of iron through sup-
pression and activation of ferroportin (cellular iron
exporter) [30]. Therefore, alteration in iron status and
prevalence of anemia are expected. According to a pre-
vious study, elevated levels of PTH may be related to
the risk of developing anemia through reduction in
erythropoiesis rate, however it is suggested that vitamin
D may increase the production of erythropoietin [29].
A systematic review and meta-analysis of RCTs were
carried out in an attempt to summarize the evidence on
the effects of vitamin D interventions on iron status
(ferritin, Hemoglobin, serum transferrin, transferrin
saturation, serum iron and TIBC) and also evaluate the




This review was conducted in accordance with the guide-
lines of the Preferred Reporting Items for Systematic Re-
views and Meta-Analyses (PRISMA). Notably, PRISMA is
primarily used for preparing systematic reviews of such re-
search interventions [31, 32]. The search terms were car-
ried out in the PubMed, Embase, Cochrane Library, and
Scopus databases by two independent investigators, and
relevant publications cited from January 2000 to January
2019 were identified. The following search terms were
used: vitamin D, 25-hydroxy vitamin D, 1, 25-hydroxy
vitamin D, ergocalciferol, cholecalciferol, calcitriol,
anemia, iron deficiency, hemoglobin, ferritin, transferrin,
iron regulation and iron status. Only articles in English
and only RCTs that were chronologically limited were
considered. The titles and abstracts of the scanned articles
were checked, and duplicate citations were then removed.
After excluding non-relevant articles, full text of the se-
lected articles (RCTs) were retrieved.
Study selection
Inclusion criteria
A structured approach was taken to set up the research
question about this review, using the following five com-
ponents that are commonly known as the Participants,
Interventions, Comparisons, Outcomes, and Study De-
sign Approach (PICOS) [33]:
1. Studies reporting the effects of vitamin D
interventions on iron status as primary or
secondary outcomes from single or combined
vitamin D supplementation with calcium, iron and
vitamin K were considered. No restrictions were
placed on the gender, age, race, and geographical
distribution of the individuals enrolled in the study.
2. Oral vitamin D supplements; such as
Cholecalciferol, Ergocalciferol and Calcitriol.
3. Studies carried out in subjects with mean age of
≥17.5 years old.
4. Study design: RCTs.
Exclusion criteria
1. Editorials, case reports, letters to the editor, review
articles, and animal studies.
2. RCTs without evaluating iron status as their
primary or secondary outcomes; or RCT studies
with no controls.
3. RCTs that did not report mean (SD) or median
interquartile changes in hemoglobin, ferritin levels,
transferrin saturation and serum iron levels in each
group.
Data extraction
Two researchers completed the data extraction independ-
ently (AM and LM) where qualitative and quantitative in-
formation were extracted from each study. Any
disagreement between the researchers with respect to the
inclusion criteria of a study was resolved by the insight of
a third researcher (AN). P-value of < 0.05 was considered
statistically significant for all of the included RCT studies.
The information that were extracted included the name of
first author, year of publication, country of origin, study
design, sample size, subjects’ age, serum vitamin D base-
line levels, dose and types of vitamin D supplements, main
study outcomes, and conclusions.
Quality and risk of bias
The quality of each study was evaluated independently
by two researchers (AN and MV) who used bias tool
method in the guidelines of Cochrane Collaboration
[34]. In accordance with this method, each study was
evaluated and good quality was obtained when the total
low risk of bias was ≥3 out of 5 items; however, if the
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total low risk of bias was ≤2 out of 5 items, it was con-
sidered as fair quality; and studies with ≤1 low risk of
bias out of 5 items were regarded as poor quality [34].
Statistical analysis
In the current review, all the statistical analysis was per-
formed on RevMan 5.3 software (Cochrane IMS, Oxford,
UK) with a random and fixed effect model. Random ef-
fect model was used for random variances, when the
number of studies entered was limited and there was a
difference between the number and characteristics of the
individuals [35]. Small and large sample sizes had the
same effect in the final conclusion when using this
model. The fixed effect model was used for studies with
fixed parameters or non-random quantities. We ex-
tracted and accumulated continuous data from all RCTs,
then analyzed the variables in order to obtain overall
weighted mean difference (WMD) with 95% confidence
intervals (CIs) by the inverse variance approach. The
heterogeneity by Cochrane I2 value was calculated with
weighted Mantele-Haenszel method as it was suggested
in Cochrane handbook [36]. In trials with several dur-
ation of supplementations, mean and standard deviations
were analysed separately. Publication bias was evaluated
according to the Begg and Egger test, by using Compre-
hensive Meta-Analysis (CMA) V2 software (Biostat, NJ)
[37, 38]. It was considered statistically significant if
P value was less than 0.05.
Subgroup analysis
Predetermined subgroup analyses were performed ac-
cording to Deeks et al. [39] study, to evaluate the poten-
tial effects of vitamin D interventions on participants
with different health conditions. In this method, studies
were explored according to the potential heterogeneity
of inducer factors, thus separate statistical analyses were
performed in each study subgroups. Thereafter, studies
were categorized according to the health status of indi-
viduals, and then separate meta-analysis was conducted.
A significant reduction in the extent of heterogeneity in
each subgroup, confirmed the heterogeneity in the
health status of individuals. We categorized subjects in
RCTs to seven groups as such: healthy adults, anemic
patients, chronic kidney disease patients, heart failure
patients, hypertensive patients, critically ill patients and
athletes. The levels of hemoglobin and ferritin in partici-
pants from these groups were assessed and compared
when supplemented with vitamin D.
Results
PRISMA flow diagram in Fig. 1, illustrates the selection
of included studies and screening process in this review.
In total, 3510 articles were found in the initial search,
and 3496 of these articles were excluded after reading
the titles and abstracts where supplementation of
interest was not evaluated. Also, duplicates were re-
moved. Finally, 14 studies met the inclusion criteria
(Additional file 1: Table S1) and were suitable for
quantitative synthesis [40–53].
Study characteristics
All studies except two were parallel double blind random-
ized clinical trials [45, 48]. The main characteristics of the
studies are illustrated in Table 1. Studies were published
online between 2014 and 2019. The range of sample size
was from 10 to 276 participants. Cholecalciferol was the
main form of vitamin D that were supplemented in these
studies. The duration of supplementation with vitamin D
also varied from 3 h to 6months [40–53].
Participant characteristics
The average age of participants ranged from 17.5 to 68
years old. Males made up more than 50% of participant’s
gender distribution. Mean baseline of 25 (OH) D levels
ranged between 10 and 30 ng/ml, as reported in 14 stud-
ies (Table 1).
Intervention characteristics
Different types of vitamin D were used in these studies,
four studies received vitamin D fortified food with chole-
calciferol [40, 46–48], eight studies received oral vitamin
D (cholecalciferol) supplements [42, 44, 45, 49–53] and
in one study subjects were supplemented with ergocal-
ciferol and another one with calcitriol [41, 43]. The
minimum vitamin D dosage was 20 IU and maximum
was 500,000 IU according to these studies (Table 1).
Outcome measures
All of these 14 RCT studies reported hemoglobin levels,
as their primary outcomes. While, iron markers such as
levels of ferritin, serum iron, and transferrin saturation
were measured as their secondary outcomes. Results are
illustrated in Table 1.
Risk of Bias assessment
According to Figs. 2, 3, 4 and 5, the Cochrane risk of bias
checklist shows the risk of bias in these randomized clin-
ical trial studies [34]. We evaluated each variable: se-
quence generation (selection bias), allocating concealment
(selection bias), blinding participants and personnel (per-
formance bias), incomplete outcome data (attrition bias),
and selective reporting (reporting bias). Each item with
low risk and appropriate information was marked as (+),
unclear risk and inadequate information marked as (?),
high risk and unsuitable information marked as (−). Fi-
nally, we assessed the overall quality, nine RCTs had a low
risk of bias rate (good) [40–44, 46, 47, 49–53]; two RCTs
had a moderate risk of bias (fair) [45, 48].
Arabi et al. Nutrition Journal           (2020) 19:11 Page 3 of 11
Meta-analyses
Outcomes
The remaining data from three studies examined differ-
ences in iron status markers between intervention and
control groups. Markers such as hemoglobin, ferritin,
transferrin saturation (TS) and serum iron (SI) levels
were included in the pooled analysis component.
Primary outcome
Overall effect of vitamin D on hemoglobin Ten clin-
ical trials (N = 1385) reported overall hemoglobin levels.
When pooled analysis were performed, vitamin D ad-
ministration did not improve hemoglobin levels [SMD
(95% CI) = 0.01 [− 0.28, 0.29]; p = 0.76; I2 = 82%; Phet <
0.00001]. Significant heterogeneity existed in the data.
We categorized our data to seven groups based on par-
ticipants’ health condition. The subgroup analysis is
demonstrated as pooled effect of vitamin D supplemen-
tation on hemoglobin in healthy adults 0.13 [95% CI = −
0.16, 0.42]; I2 = not applicable, anemic patients 0.02 [95%
CI = − 0.20, 0.24]; I2 = 30%, chronic kidney disease pa-
tients − 1.07 [95% CI = − 1.46, − 0.69]; I2 = 0%, heart fail-
ure patients − 0.05 [95% CI = − 0.35, 0.25]; I2 = not
applicable, hypertensive patients 0.00 [95% CI = − 0.29,
0.29]; I2 = not applicable, critically ill adults 3.85 [95%
CI = 2.72, 4.98]; I2 = 0% and athletic subjects 0.15 [95%
CI = − 0.13, 0.44]; I2 = 0% (Fig. 2).
Secondary outcome
Overall effect of vitamin D on ferritin In 11 of in-
cluded studies (N = 1363) vitamin D supplementation
did not improve ferritin concentrations in overall [SMD
(95% CI) = − 0.01 [− 0.20, 0.18]; p = 0.91; I2 = 60%; Phet
< 0.0010]. Significant heterogeneity existed in the data.
For clarifying the impact of vitamin D, subgroup analysis
was performed in five groups. The subgroup analysis
showed the pooled effect of vitamin D interventions on
ferritin levels in healthy adults: -0.17 [95% CI = − 0.72,
Fig. 1 PRISMA flow-diagram of the study selection process
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0.39]; I2 = 74%, anemic patients: -0.18 [95% CI = − 0.36,
0.01]; I2 = 0%, chronic kidney disease patients: 0.45 [95%
CI = 0.06, 0.85]; I2 = 58%, critically ill adults: -0.92 [95%
CI = − 1.71, − 0.14]; I2 = not applicable and athletic sub-
jects: 0.09 [95% CI = − 0.61, 0.78]; I2 = 65% (Fig. 3).
Overall effect of vitamin D on transferrin saturation
Pooled data of six studies (N = 1008) showed a significant
difference between the case and control groups on trans-
ferrin saturation, with low heterogeneity [MD (95%CI):
1.54 [0.31, 2.76]; p = 0.01; I2 = 21%; Phet =0.24] (Fig. 4).
Fig. 2 Forest plot showing results of a meta-analysis on the effects of vitamin D supplementation on hemoglobin. Data were reported as SMDs
with 95% CIs. (Toxqui study at 4, 8, 12 and 16 weeks after intervention, Panwar study at 1, 4 and 6 weeks after supplementation)
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Overall effect of vitamin D on serum iron The
weighted results from four studies (N = 736) showed, an
improving effect of vitamin D on serum iron levels ver-
sus placebo group, without any existed heterogeneity
[MD (95%CI): 1.54 [0.31, 2.76]; p = 0.01; I2 = 0%; Phet =
0.24] (Fig. 5).
Sensitivity analysis and publication bias Results of
sensitivity analysis was conducted by using leave-one-
out method, in this method removal of any of the stud-
ies from total RCTs or subgroups analysis could cause
no substantial change in the impact of vitamin D supple-
ments on hemoglobin and ferritin levels. For instance,
two studies with measured hemoglobin and ferritin
levels after supplementation with vitamin D and a
moderate quality were removed [45, 48]. Thus, the ef-
fect of vitamin D intervention did not significantly
change the overall outcome of hemoglobin levels:
[SMD (95% CI) = 0.03 [− 0.27, 0.33]; p = 0.86; I2 = 84%;
Phet < 0.00001], and ferritin levels: [SMD (95% CI) =
0.01 [− 0.19, 0.21]; p = 0.92; I2 = 64%; Phet =0.0005].
Despite the weak asymmetry observed in funnel plot,
current results showed that vitamin D supplementa-
tion effects on hemoglobin concentrations, had no
evidence of publication bias (Begg’s test, P = 0.58;
Egger’s test, P = 0.92) [37, 54].
Fig. 3 Forest plot showing results of a meta-analysis on the effects of vitamin D supplementation on ferritin. Data were reported as SMDs with
95% CIs. (Toxqui study at 4, 8, 12 and 16 weeks after intervention, Panwar study at 1, 4 and 6 weeks after supplementation)
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Discussion
The present systematic and meta-analysis study included
14 studies with 1385 participants from different coun-
tries. Vitamin D3 treatments (20 to 500,000 IU) on
adults did not have a significant impact on the levels of
serum hemoglobin overall. While, pooled analysis re-
vealed a significant effect of vitamin D supplements on
transferrin saturation and iron levels. Subgroup analysis
according to the health condition of participants,
propose that supplementation with vitamin D signifi-
cantly increased hemoglobin levels in critically ill
patients. Sensitivity analysis for studies with low quality
indicated an insignificant change on the total effect. To
the extent of our knowledge, this is the first pooled ana-
lysis which has evaluated the overall effect of vitamin D
interventions on iron status in subjects with different
health conditions. According to a cross sectional meta-
analysis, there was a positive association between vita-
min D deficiency and incidence of anemia [55]. This
study, was performed on 5183 subjects, indicated partici-
pants who were vitamin D deficient had 64% higher risk
of developing anemia compared to those who were
Fig. 4 Forest plot showing results of a meta-analysis on the effects of vitamin D supplementation on transferrin saturation. Data were reported as
MDs with 95% CIs. (Toxqui study at 4, 8, 12 and 16 weeks after intervention, Panwar study at 1, 4 and 6 weeks after supplementation)
Fig. 5 Forest plot showing results of a meta-analysis on the effects of vitamin D supplementation on iron levels. Data were reported as SMDs
with 95% CIs. (Toxqui study at 4, 8, 12 and 16 weeks after intervention, Panwar study at 1, 4 and 6 weeks after supplementation)
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vitamin D sufficient [55]. In another meta-analysis by
Basutkar et al. [56], .vitamin D supplementation in iron
insufficient subjects did not improve their clinical out-
comes such as hemoglobin and ferritin levels. Similarly,
the clinical trials reported in the present systematic re-
view, showed no significant impact of different doses of
vitamin D on hemoglobin and ferritin levels, thus, this
could be due to the high heterogeneity of the combined
studies [40, 42–46, 49–51, 53]. However, it should be
noted that active form of vitamin D can affect erythro-
poiesis through stimulating the erythroid progenitor
cells for proliferation and maturation, therefore calcitriol
deficiency may damage erythropoiesis, and this may ex-
plain positive effect of vitamin D on iron status [57].
Our primary finding is consistent with a recent meta-
analysis, where they showed vitamin D treatment had no
association with improvements in patients with anemia
[45, 46]. However, according to a narrative review con-
ducted by Smith et al. [58], .cholecalciferol supplementa-
tion improved anemic condition, through modulating
pro and anti-inflammatory cytokines, which leads to re-
duction in the levels of hepcidin and progress into
anemic status [58]. Finally, vitamin D may boost erythro-
poiesis by increase in iron availability. Some iron inhibi-
tor recycling agents, including the parathyroid hormone
(PTH) and fibroblast growth factor 23 (FGF23) may lead
to destructive effects on iron metabolism. However, iron
recycling effect of vitamin D probably depends on sev-
eral conditions such as existed inflammation, high levels
of parathyroid hormone and fibroblast growth factor 23
[29, 59]. Notably, in healthy subjects due to their bal-
anced levels of parathyroid hormones and Fibroblast
growth factor-23 (FGF-23), also no or low inflammation
rate, vitamin D could not be effective for improving the
iron status. However, according to the subgroup analysis,
in critically ill patients with high inflammation rate and
high PTH concentrations, vitamin D may improve their
iron status through increase in erythropoietin and stimu-
lation of erythroid progenitor formation while, PTH levels
are suppressed. In this study, current outcomes suggest
that vitamin D interventions significantly induce transfer-
rin saturation and iron levels. Active vitamin D (1, 25(OH)
D3) may have beneficial impacts on the levels of parathy-
roid hormone (PTH), through increase in the absorption
rate of calcium and suppression in the release of PTH
from parathyroid glands [60]. Previous studies have pro-
posed that depletion of PTH secretion could be related to
improved erythropoiesis by inducing erythropoietin and
erythroid progenitor formation as well as decreased fibro-
sis of the bone marrow [29, 61, 62]. Moreover, since fibro-
blast growth factor 23 is a negative modulator for iron
hemostasis and erythropoiesis, vitamin D may reduce this
factor thus improve the metabolism of iron, followed by
an increase in the levels of iron [63, 64]. The present
meta-analysis has several limitations, duration of
RCTs were short, also one of the included RCTs was
not assessed in the pooled analysis since it lacked pla-
cebo group [65]. Different types of vitamin D such as
ergocalciferol and calcitriol were supplemented in
these trials [41, 43]. The possible reasons for the het-
erogeneity in data could be associated with the differ-
ences in the duration of supplementation, sex, race,
geographical location, seasonal change, mean age,
sample size, health conditions, vitamin D dosage and
co-supplementations. Therefore, we performed the
random-effects model, in order to determine the het-
erogeneity among these studies. This study lacks evi-
dence regarding the mechanism of action between
vitamin D and iron levels.
Conclusion
In conclusion, current systematic review and meta-
analysis demonstrated that vitamin D supplements can
improve hemoglobin and ferritin status in critically ill
and chronic kidney disease patients’ subgroups. Whereas
in other subgroups (healthy adults, anemic patients,
chronic kidney disease patients, heart failure patients,
hypertensive patients, critically ill patients and athletes)
non-statistically significant difference were observed on
hemoglobin and ferritin levels. The current study sug-
gests that vitamin D supplementation on inflammatory
diseases (CKD and critical illness) could effectively im-
prove anemia status. Although there is still limited
evidence in order to support and clarify the exact mech-
anism of action between vitamin D and iron levels.
Therefore, further high-quality, well designed and long
term RCTs in this field are extensively required.
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